TABLE 7.

Comparison with previously published real‐world studies

Characteristic	Tepper [19]	Ornello [23]	Raffaelli [24]	Lambru [21]	Scheffler [25]	Ranieri [26]	Robblee [27]	This audit
CM patients at baseline, n	381	84	139	162	74	21	95	92
F, %	87	88	84	83	80	90	89	79
Completed analysis, n	375	76	45	100	na	21	39	72
Follow‐up duration, months	3	6	3	3	3	3	6	3
Age, years	42	47	54	46	46	44	49	46
Aura, %	40	30	22	33	na	na	40	24
Medication overuse, %	41	72	na	54	66	29	19	51
Previous botulinum toxin use, %	67	49	100	91	100	na	83	47
Previous preventives, n	<3	88% tried 2–4	5	8	>6	>2	11	8
Baseline MHD/MMD/RxD, days	21/18/9	na/20/14	18/11/7	23/20/12	21/16/12	20/10/10	24/18/na	28/15/12
Change in MHD/MMD/RxD, days	na/‐7/‐4	na/‐15/‐8	‐5/‐5/‐6	‐6/‐6/‐3	‐6/‐5/‐3	‐9/‐6/‐6	‐7/‐9/na	0/‐5/‐1
MMD 50% responder rate	41	74	na	35	42	na	55	36
Constipation rate, %	4	14	19	20	24	10	24	50

Abbreviations: CM, chronic migraine; F, female; MHD, monthly headache days; MMD, monthly migraine days; na, not available; RxD, acute treatment days.